- BNF:
- 8.1.2
- Status:
- Red
- Decision Date:
- May 2016
Comments
RED:
NICE TA389: pegylated liposomal doxorubicin hydrochloride is recommended as an option for treating recurrent ovarian cancer. (Decision date - May 2016).
NHS England drug - to be used in line with NHS England commissioning intentions.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again